A. Lapczynski

Fragrance material review on geraniol

A toxicologic and dermatologic review of geraniol when used as a fragrance ingredient is presented.

Fragrance material review on nerolidol (isomer unspecified).

A toxicologic and dermatologic review of nerolidol when used as a fragrance ingredient is presented.

Fragrance material review on l-linalool

A toxicologic and dermatologic review of l-linalool when used as a fragrance ingredient is presented.

Fragrance material review on farnesol.

A toxicologic and dermatologic review of farnesol when used as a fragrance ingredient is presented.

Fragrance material review on d-linalool

A toxicologic and dermatologic review of d-linalool when used as a fragrance ingredient is presented.

Fragrance material review on nerol

A toxicologic and dermatologic review of nerol when used as a fragrance ingredient is presented.

Fragrance material review on geranyl linalool

A toxicologic and dermatologic review of geranyl linalool when used as a fragrance ingredient is presented.

RIFM fragrance ingredient safety assessment, ethyl anthranilate, CAS registry number 87-25-2

a Research Institute for Fragrance Materials, Inc., 50 Tice Boulevard, Woodcliff Lake, NJ 07677, USA b Department of Dermatology, Member RIFM Expert Panel, Columbia University Medical Center, 161 Fort Washington Ave., New York, NY 10032, USA c Department of Occupational & Environmental Dermatology, Member RIFM Expert Panel, Malmo University Hospital, Sodra Forstadsgatan 101, Entrance 47, Malmo SE-20502, Sweden d Member RIFM Expert Panel, University of Nebraska Lincoln, 230 Whittier Research Center, Lincoln, NE 68583-0857, USA e Department of Pathology, School of Veterinary Medicine and Animal Science, Member RIFM Expert Panel, University of Sao Paulo, Av. Prof. dr. Orlando Marques de Paiva, 87, Sao Paulo CEP 05508-900, Brazil f Department of Toxicology, Member RIFM Expert Panel, University of Wuerzburg, Versbacher Str. 9, Würzburg 97078, Germany g Member RIFM Expert Panel, Oregon Health Science University, 3181 SW Sam Jackson Park Rd., Portland, OR 97239, USA h Department of Biochemistry, Center in Molecular Toxicology, Member RIFM Expert Panel, Vanderbilt University School of Medicine, 638 Robinson Research Building, 2200 Pierce Avenue, Nashville, TN 37232-0146, USA i Member RIFM Expert Panel, Department of Dermatology, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 6068507, Japan j Department of Comparative Medicine, College of Veterinary Medicine, Member RIFM Expert Panel, The University of Tennessee, 2407 River Dr., Knoxville, TN 37996-4500, USA k Member RIFM Expert Panel, Department of Pharmacology, College of Medicine, University of Arizona, 1501 North Campbell Avenue, P.O. Box 245050, Tucson, AZ 85724-5050, USA

Evaluation of the developmental toxicity of acetyl cedrene.

The developmental toxicity of acetyl cedrene (AC), a widely used fragrance ingredient, was evaluated in pregnant Sprague-Dawley rats (25/group). Gavaged dosages of 0 (corn oil), 25, 50, or 100 mg/kg/day were administered on days 7 through 17 of gestation (GDs 7 to 17). First and last day dosing suspensions were analyzed for AC content. All rats were observed daily for viability, clinical signs, abortions, and premature deliveries. Body weights were recorded at frequent intervals. Cesarean-sectioning and necropsy examinations were performed on GD 21. Uteri were examined for number and distribution of implantations, live and dead fetuses, and early and late resorptions. The number of corpora lutea in each ovary was also recorded. Fetuses were weighed and examined for gender and gross external changes and soft tissue or skeletal alterations. Totals of 25, 23, 21, and 24 rats became pregnant in the 0 (control), 25, 50 and 100 mg/kg/day groups, respectively, and analysis of dosage preparations verified that administered dosages reflected calculated dosages ±10%. No deaths or premature deliveries occurred in the study. Clinical signs included excessive salivation, which was attributed to the administration of AC. When compared to controls, significant reductions in feed consumption and body weight gains occurred only at 100 mg/kg/day. Both absolute (g/day) and relative (g/kg/day) feed consumption values were significantly decreased on GDs 7 to 12. Relative values were decreased significantly on GDs 15 to 18. Body weight gains were significantly reduced on GDs 7 to 10. Mean maternal body weights remained significantly lower than controls on GDs 9 to 14, but a marked compensatory increase in feed consumption on GDs 15 to 18 prevented further deterioration in body weight gains. No cesarean-sectioning or litter parameters were affected by dosages of AC and necropsy of the dams after cesarean section did not reveal any gross changes attributable to AC. No gross external, soft tissue, or skeletal fetal alterations (malformations or variations) were attributed by dosages AC. The average number of ossifications sites per fetus per litter did not differ among the groups. Based on these data, maternal and developmental no-observable-adverse-effect levels (NOAELs) of 50 and 100 mg/kg/day, respectively, were established for AC.

RIFM fragrance ingredient safety assessment, Linalool, CAS registry number 78-70-6.

a Research Institute for Fragrance Materials, Inc., 50 Tice Boulevard, Woodcliff Lake, NJ 07677 USA b Member RIFM Expert Panel, Department of Dermatology, Columbia University Medical Center, 161 Fort Washington Ave., New York, NY 10032, USA c Member RIFM Expert Panel, Department of Occupational & Environmental Dermatology, Malmo University Hospital, Sodra Forstadsgatan 101, Entrance 47, Malmo SE-20502, Sweden d Member RIFM Expert Panel, University of Nebraska Lincoln, 230 Whittier Research Center, Lincoln, NE 68583-0857 USA e Member RIFM Expert Panel, School of Veterinary Medicine and Animal Science, Department of Pathology, University of Sao Paulo, Av. Prof. dr. Orlando Marques de Paiva, 87, Sao Paulo CEP 05508-900, Brazil f Member RIFM Expert Panel, Department of Toxicology, University of Wuerzburg, Versbacher Str. 9, Wurzburg 97078, Germany g Member RIFM Expert Panel, Oregon Health Science University, 3181 SW Sam Jackson Park Rd., Portland, OR 97239 USA h Member RIFM Expert Panel, Department of Biochemistry, Center in Molecular Toxicology, Vanderbilt University School of Medicine, 638 Robinson Research Building, 2200 Pierce Avenue, Nashville, TN 37232-0146, USA i Member RIFM Expert Panel, Department of Dermatology, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 6068507, Japan j Member RIFM Expert Panel, College of Veterinary Medicine, Department of Comparative Medicine, The University of Tennessee, 2407 River Dr., Knoxville, TN 37996-4500, USA k Member RIFM Expert Panel, Department of Pharmacology, College of Medicine, University of Arizona, 1501 North Campbell Avenue, P.O. Box 245050, Tucson, AZ 85724-5050, USA